MedTrace Logo

Evaluation of MT-12 Implant Survival and Marginal Bone Loss

NCT02975674 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-05-23

No results posted yet for this study

Summary

The trial is designed as a consecutive enrollment prospective one-center study. A minimum of 30 patients will be included in the study. At implant installation, the patient will be randomized to receive one of the two types of implants (Control: internal hexagon connection implants (CON.INT); Test: Morse taper connection implants (MT-12)). Samples of peri-implant crevicular fluid (PICF) and intrasulcular plaque will be collected at -21 (second-stage surgery), -14 (impressions), 0 (Baseline: prosthesis delivery), 7 days and 1, 3, 6, 12 months. Prosthesis will be fabricated and delivered as usual, i.e., approximately two weeks after the impressions are taken.

Conditions

  • Jaw, Edentulous, Partially

Interventions

DEVICE

MT-12 dental implant

Placement of the MT-12 dental implant with Morse taper implant-abutment connection

DEVICE

CON.INT dental implant

Placement of the CON.INT dental implant with internal hexagon implant-abutment connection

Sponsors & Collaborators

  • Universidad de Granada

    lead OTHER

Principal Investigators

  • Pablo Galindo-Moreno, DDS, PhD · Universidad de Granada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02975674 on ClinicalTrials.gov